ProPhase Labs, Inc. (PRPH)

Market Cap	17.38M
Revenue (ttm)	5.85M
Net Income (ttm)	-43.13M
Shares Out	41.54M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	479,914
Open	0.4000
Previous Close	0.4037
Day's Range	0.4000 - 0.4280
52-Week Range	0.2179 - 3.7400
Beta	-0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2025

About PRPH

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, inc...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jan 16, 1997
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: PRPH
• Website: https://www.prophaselabs.com

Financial Performance

In 2024, ProPhase Labs's revenue was $6.77 million, a decrease of -80.65% compared to the previous year's $34.98 million. Losses were -$53.36 million, 218.0% more than in 2023.